HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weiner, W. J. Articles by Goldenberg, J. N. Search for Related Content PubMed PubMed Citation Articles by Weiner, W. J. Articles by Goldenberg, J. N.

Levodopa, melanoma, and Parkinson's disease

University of Miami School of Medicine, Department of Neurology, Miami, FL.

Previous reports and the Physicians' Desk Reference caution against the use of levodopa in Parkinson's disease (PD) patients with melanoma. A critical review of the literature reveals only anecdotal evidence to support a link between levodopa and melanoma. In fact, levodopa has an antitumor effect on melanoma. We report nine patients with PD and melanoma who were treated with levodopa/carbidopa (L/C). Current evidence suggests that L/C can be used safely in PD patients with a history of melanoma.

Presented in part at the 44th annual meeting of the American Academy of Neurology, San Diego, CA, May 1992.

Address correspondence and reprint requests to Dr. William J. Weiner, Department of Neurology, University of Miami School of Medicine, 1501 N.W. 9th Avenue, Miami, FL 33136.

Supported in part by a grant from the National Parkinson Foundation.

Received June 16, 1992. Accepted for publication in final form August 10, 1992.

This article has been cited by other articles:

				J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]